VEGFD (VEGF4) Antibody Blocking peptide
€363.00
In stock
SKU
AC-BP2043a
Background:
Vascular endothelial growth factors (VEGFs) are a family of secreted glycoproteins which act as mitogens primarily for vascular endothelial cells. VEGF-C (VEGF3) and VEGF-D (VEGF4) are recently identified members which share the conserved VEGF Homology Domain. They both have long N- and C-terminal propeptide extensions, and undergo proteolytic processing. Both VEGF-C and VEGF-D are widely expressed with highest expression in lymphnodes. The receptors VEGFR2 and VEGFR3 are expressed in vascular endothelial cells and lymphatic endothelial cells. VEGF-C and VEGFR3 are usually co-expressed at growing lymphatic endothelial cells. The VEGF-C/VEGFR3 signaling pathway has been shown to be crucial for lymphatic development. Recently increased expression of VEGF-C has been linked to a variety of human tumors and correlates with increased lymphatic density and lymph node metastasis.
Other Names:
Vascular endothelial growth factor D, VEGF-D, c-Fos-induced growth factor, FIGF, FIGF, VEGFD
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP2043a was selected from the region of human VEGF4. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Gene Name: VEGFD (HGNC:3708)
Gene ID: 2277
Primary Accession: O43915
Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
Vascular endothelial growth factors (VEGFs) are a family of secreted glycoproteins which act as mitogens primarily for vascular endothelial cells. VEGF-C (VEGF3) and VEGF-D (VEGF4) are recently identified members which share the conserved VEGF Homology Domain. They both have long N- and C-terminal propeptide extensions, and undergo proteolytic processing. Both VEGF-C and VEGF-D are widely expressed with highest expression in lymphnodes. The receptors VEGFR2 and VEGFR3 are expressed in vascular endothelial cells and lymphatic endothelial cells. VEGF-C and VEGFR3 are usually co-expressed at growing lymphatic endothelial cells. The VEGF-C/VEGFR3 signaling pathway has been shown to be crucial for lymphatic development. Recently increased expression of VEGF-C has been linked to a variety of human tumors and correlates with increased lymphatic density and lymph node metastasis.
Other Names:
Vascular endothelial growth factor D, VEGF-D, c-Fos-induced growth factor, FIGF, FIGF, VEGFD
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP2043a was selected from the region of human VEGF4. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Gene Name: VEGFD (HGNC:3708)
Gene ID: 2277
Primary Accession: O43915
Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
| Is Featured? | No |
|---|
Write Your Own Review